耳穴贴压联合芪苈强心胶囊治疗阳虚水泛型慢性心力衰竭的临床疗效观察

注册号:

Registration number:

ITMCTR2025001409

最近更新日期:

Date of Last Refreshed on:

2025-07-15

注册时间:

Date of Registration:

2025-07-15

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

耳穴贴压联合芪苈强心胶囊治疗阳虚水泛型慢性心力衰竭的临床疗效观察

Public title:

Clinical Efficacy Observation of Auricular Point Pressing Combined with Qili Qiangxin Capsules in the Treatment of Chronic Heart Failure of Yang Deficiency and Water Flooding Pattern

注册题目简写:

English Acronym:

研究课题的正式科学名称:

耳穴贴压联合芪苈强心胶囊治疗阳虚水泛型慢性心力衰竭的临床疗效观察

Scientific title:

Clinical Efficacy Observation of Auricular Point Pressing Combined with Qili Qiangxin Capsules in the Treatment of Chronic Heart Failure of Yang Deficiency and Water Flooding Pattern

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴珂

研究负责人:

吴珂

Applicant:

Wu Ke

Study leader:

Wu Ke

申请注册联系人电话:

Applicant telephone:

+86 173 5526 8267

研究负责人电话:

Study leader's telephone:

+86 173 5526 8267

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

17355268267@163.cm

研究负责人电子邮件:

Study leader's E-mail:

17355268267@163.cm

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市普陀区兰溪路164号

研究负责人通讯地址:

上海市普陀区兰溪路164号

Applicant address:

No. 164 Lanxi Road Putuo District Shanghai

Study leader's address:

No. 164 Lanxi Road Putuo District Shanghai

申请注册联系人邮政编码:

Applicant postcode:

200062

研究负责人邮政编码:

Study leader's postcode:

200062

申请人所在单位:

上海中医药大学附属普陀医院

Applicant's institution:

Shanghai Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

PTEC-A-2025-15-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海中医药大学附属普陀医院伦理委员会

Name of the ethic committee:

Ethics Committee of Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/3/21 0:00:00

伦理委员会联系人:

潘姗姗

Contact Name of the ethic committee:

Pan Shanshan

伦理委员会联系地址:

上海市普陀区兰溪路164号

Contact Address of the ethic committee:

No. 164 Lanxi Road Putuo District Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 2223 4110

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xlt8171@126.com

研究实施负责(组长)单位:

上海中医药大学附属普陀医院

Primary sponsor:

Shanghai Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市普陀区兰溪路164号

Primary sponsor's address:

No. 164 Lanxi Road Putuo District Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属普陀医院

具体地址:

上海市普陀区兰溪路164号普陀区中心医院

Institution
hospital:

Shanghai Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Address:

Shanghai Putuo District Central Hospital No. 164 Lanxi Road Putuo District Shanghai.

经费或物资来源:

上海中医药大学研究生课题

Source(s) of funding:

Research Project of Postgraduate Students at Shanghai University of Traditional Chinese Medicine

研究疾病:

阳虚水泛型慢性心力衰竭

研究疾病代码:

Target disease:

Chronic heart failure of the yang - deficiency and water - flooding type.

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究的目的是通过随机、对照的临床试验,在现代医学规范化治疗基础上,将耳穴贴压联合芪苈强心胶囊与单纯药物治疗进行对比研究,旨在评估耳穴贴压联合芪苈强心胶囊治疗阳虚水泛型慢性心力衰竭的临床疗效。为临床综合治疗慢性心衰提供新思路,为患者提供更有效的治疗选择,阴阳兼顾、标本兼治,把药物内在药理作用与外治调节经络气血结合,实现多靶点协同干预,并初步探讨其可能的临床效应机制。

Objectives of Study:

The purpose of this study is to conduct a randomized controlled clinical trial. Based on standardized modern medical treatment it compares auricular point sticking combined with Qili Qiangxin Capsule with monotherapy aiming to evaluate the clinical efficacy of auricular point sticking combined with Qili Qiangxin Capsule in the treatment of chronic heart failure (CHF) with yang deficiency and water retention syndrome. This study intends to provide new ideas for the comprehensive clinical treatment of CHF offer more effective therapeutic options for patients and adopt a holistic approach that balances yin and yang while addressing both the root cause and symptoms. By integrating the internal pharmacological effects of drugs with external regulation of meridian qi and blood it aims to achieve multi-target collaborative intervention and preliminarily explore its possible clinical action mechanisms.

药物成份或治疗方案详述:

选择88例慢性心力衰竭阳虚水泛型患型者,并采用SPSS25.0随机分配序列号,将患者随机分为对照组44例,观察组44例,两组均连续干预8周。 (1)对照组:予西医常规治疗和芪苈强心胶囊。西医常规治疗具体参照《中国心力衰竭诊断和治疗指南2024》中提出的治疗方法处理。予患者肾素-血管紧张素系统(RASI)抑制剂、钠-葡萄糖共同转运蛋白2抑制剂(SGLT2i)、β受体阻滞剂、盐皮质激素拮抗剂(MRA)、利尿剂等治疗。芪苈强心胶囊生产厂家:石家庄以岭药业股份有限公司,国家准字号:Z20040141,用药方式:口服,用药剂量:每天3次,每次4粒。疗程为8周。 (2)观察组:在对照组治疗基础上,予耳穴贴压治疗,耳穴取交感、神门、内分泌、皮质下、心、肾、三焦穴。用止血钳将粘有王不留行籽的0.5 cm×0.5 cm大小医用胶布粘贴相应穴位上,用手按压直至患者自觉耳廓出现麻、胀、热的感觉为宜,每次2分钟(min), 每天3~4次,每7天至医院更换耳穴胶布和埋籽,双耳交替进行。干预期间若埋籽脱落立即进行补贴,住院患者由课题负责人补贴,门诊患者可联系课题负责人进行补贴。疗程为8周。

Description for medicine or protocol of treatment in detail:

A total of 88 patients with chronic heart failure of yang deficiency and water retention type were selected and their random allocation serial numbers were generated by SPSS25.0. Then the patients were randomly divided into a control group of 44 cases and an observation group of 44 cases with both groups receiving continuous intervention for 8 weeks. The control group was given routine Western medicine treatment (specifically referring to the treatment methods proposed in *Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024* including renin-angiotensin system (RASI) inhibitors sodium-glucose cotransporter 2 inhibitors (SGLT2i) β-blockers mineralocorticoid antagonists (MRA) diuretics etc.) and Qili Qiangxin Capsule (manufactured by Shijiazhuang Yiling Pharmaceutical Co. Ltd. with the national approval number Z20040141 taken orally 4 capsules each time 3 times a day for 8 weeks). The observation group on the basis of the control group's treatment was given auricular point sticking treatment with the auricular points including Sympathetic Shenmen Endocrine Subcortex Heart Kidney and Sanjiao points. Medical adhesive tape of 0.5 cm×0.5 cm with Vaccaria seeds attached was pasted onto the corresponding points with hemostatic forceps and the points were pressed by hand until the patient felt numbness distension and heat in the auricle for 2 minutes each time 3 to 4 times a day. The auricular point adhesive tape and embedded seeds were replaced at the hospital every 7 days alternating between both ears. If the embedded seeds fell off during the intervention they were immediately reapplied (for inpatients the project leader was responsible for reapplication and outpatients could contact the project leader for reapplication) and the treatment course was 8 weeks.

纳入标准:

(1)符合阳虚水泛型慢性心力衰竭中西医及证型标准者; (2)年龄18至90岁者,性别不限; (3)NYHA心功能分级为II~III级的慢性心力衰竭者; (4)左心室射血分数小于40%(HFrEF); (5)对本研究知情并自愿参加本研究,签署知情同意书者。

Inclusion criteria

(1) Those who meet the (Chinese and Western medicine) and syndrome type criteria for chronic heart failure of the yang deficiency and water flooding type; (2) Those aged between 18 and 90 years old regardless of gender; (3) Chronic heart failure patients with NYHA cardiac function classification of grade II to III; (4) Those with a left ventricular ejection fraction less than 40% (HFrEF); (5) Those who are informed about this study voluntarily participate in this study and sign the informed consent form.

排除标准:

(1)有严重基础疾病及精神病患者; (2)对本研究药物过敏者或对贴压胶布、王不留行籽过敏者; (3)伴有严重感染或活动性风湿热、细菌性心内膜炎等疾病; (4)不能严格遵守本试验要求及正在参加其它药物临床试验者; (5)哺乳妊娠、准备妊娠和哺乳期的妇女; (6)对耳穴贴压疗法不适应者; (7)不同意参加本试验者。

Exclusion criteria:

(1) Patients with severe underlying diseases or mental illnesses; (2) Patients allergic to the drugs used in this study or allergic to the adhesive tape for application or Vaccaria seeds; (3) Patients with severe infections or active diseases such as rheumatic fever bacterial endocarditis etc.; (4) Patients who cannot strictly comply with the requirements of this trial or are currently participating in other drug clinical trials; (5) Women who are pregnant planning to become pregnant or breastfeeding; (6) Patients who are not adaptable to auricular point sticking therapy; (7) Patients who do not agree to participate in this trial.

研究实施时间:

Study execute time:

From 2025-03-23

To      2026-02-28

征募观察对象时间:

Recruiting time:

From 2025-07-15

To      2026-02-28

干预措施:

Interventions:

组别:

观察组

样本量:

44

Group:

observation group

Sample size:

干预措施:

予西医常规治疗和芪苈强心胶囊及耳穴贴压

干预措施代码:

Intervention:

Give routine Western medicine treatment Qili Qiangxin Capsules and auricular point pressing.

Intervention code:

组别:

对照组

样本量:

44

Group:

control group

Sample size:

干预措施:

予西医常规治疗和芪苈强心胶囊

干预措施代码:

Intervention:

Give routine Western medicine treatment and Qili Qiangxin Capsules.

Intervention code:

样本总量 Total sample size : 88

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属普陀医院

单位级别:

三级

Institution/hospital:

Shanghai Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Level of the institution:

grade three

测量指标:

Outcomes:

指标中文名:

入院前后小腿周径

指标类型:

次要指标

Outcome:

Calf circumference before and after admission

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

明尼苏达生活质量表(MLHFQ)评分

指标类型:

次要指标

Outcome:

Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医单项症状及症候评分

指标类型:

主要指标

Outcome:

Score of Traditional Chinese Medicine Single Symptoms and Syndromes

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规、尿常规、粪便常规、肝功能、肾功能、电解质

指标类型:

副作用指标

Outcome:

Blood Routine Test Urine Routine Test Stool Routine Test Liver Function Test Renal Function Test Electrolyte Test

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心功能指标:NT-proBNP、左室射血分数(LVEF)、6分钟步行距离

指标类型:

次要指标

Outcome:

Cardiac function indicators: NT - proBNP left ventricular ejection fraction (LVEF) 6 - minute walk distance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

入院前后体重

指标类型:

次要指标

Outcome:

Body weight before and after admission

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用SPSS25.0随机分配序列号

Randomization Procedure (please state who generates the random number sequence and by what method):

Use SPSS 25.0 to randomly assign serial numbers.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NO

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表记录患者姓名、研究开始及结束时间,记录患者用药时间、治疗前后的NT-proBNP、左室射血分数、6分钟步行距离、空腹体重、小腿周径、中医证候积分、明尼苏达生活质量评分、安全性指标和不良反应。 电子采集与系统管理根据原始文件录入数据Excel表格,确保真实准确性,统一管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF documented the patients' names study initiation and completion dates and medication administration timelines. Clinical parameters including NT-proBNP levels left ventricular ejection fraction (LVEF) 6-minute walking distance fasting body weight and calf circumference were recorded both pre- and post-treatment. Additionally Traditional Chinese Medicine syndrome scores Minnesota Living with Heart Failure Questionnaire (MLHFQ) assessments safety indicators and any adverse reactions were systematically documented for comprehensive evaluation. Electronic collection and system management involve entering data into Excel spreadsheets based on original documents ensuring authenticity and accuracy and conducting unified data management.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统